Xencor Inc — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 61/100
What the filing says
Xencor announced a $105M settlement with Alexion resolving U.S. Ultomiris royalty disputes: $52.5M due August 2026, $52.5M due one year later, with no future U.S. royalty obligations. Additionally, Zenas paid $10M regulatory milestone for obexelimab BLA submission. Q2 2026 revenue was $51.2M (up from $43.6M YoY); R&D expenses increased to $71.9M; net loss was $21.7M or $(0.29)/share. Cash position declined to $486.4M (from $610.8M at year-end 2025) with guidance of $420–440M cash by year-end 2026.
Why this rating
Settlement is ~19% of market cap, materially strengthens near-term cash; offsets clinical R&D spending burn. Clinically on-track but pre-revenue pipeline. Positive near-term liquidity; cash runway extended through 2028.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.